FIELD: medicine.
SUBSTANCE: invention represents versions of antibodies specifically binding to an extracellular domain of human CD43 or human CEA expressed by nonhematopoietic cancer cells. Said antibodies are characterised by amino acid sequences of either three heavy and light chain CDR, or amino acid sequences VH and VL. There are also presented an antibody conjugate with a cytotoxic agent; a host cell producing the antibody; a composition for nonhematopoietic cancer; a polynucleotide; an antibody expression vector.
EFFECT: versions of a method of treating nonhematopoietic cancer.
29 cl, 16 dwg, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES RECOGNIZING CARBOHYDRATE-CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS OF APPLICATION | 2012 |
|
RU2616868C2 |
| ANTIBODIES RECOGNISING EPITOPE ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS AND METHODS FOR USING THEM | 2008 |
|
RU2528738C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| COVALENT DIANTIBODIES AND USE THEREOF | 2009 |
|
RU2593720C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| COVALENT DIABODIES AND USE THEREOF | 2009 |
|
RU2744176C2 |
| TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
